1. Home
  2. SYF vs RPRX Comparison

SYF vs RPRX Comparison

Compare SYF & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

SYF

Synchrony Financial

HOLD

Current Price

$66.96

Market Cap

24.0B

Sector

Finance

ML Signal

HOLD

Logo Royalty Pharma plc

RPRX

Royalty Pharma plc

HOLD

Current Price

$45.70

Market Cap

19.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SYF
RPRX
Founded
1932
1996
Country
United States
United States
Employees
20000
N/A
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
24.0B
19.7B
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
SYF
RPRX
Price
$66.96
$45.70
Analyst Decision
Buy
Strong Buy
Analyst Count
19
4
Target Price
$86.42
$47.75
AVG Volume (30 Days)
3.7M
2.9M
Earning Date
04-21-2026
05-07-2026
Dividend Yield
1.81%
2.07%
EPS Growth
N/A
N/A
EPS
N/A
1.78
Revenue
N/A
$2,378,193,000.00
Revenue This Year
$86.60
$38.30
Revenue Next Year
$4.95
$4.80
P/E Ratio
$7.85
$25.45
Revenue Growth
N/A
5.06
52 Week Low
$40.55
$29.66
52 Week High
$88.77
$47.86

Technical Indicators

Market Signals
Indicator
SYF
RPRX
Relative Strength Index (RSI) 44.67 54.42
Support Level $63.08 $44.94
Resistance Level $75.21 $46.14
Average True Range (ATR) 1.69 0.82
MACD 0.32 -0.24
Stochastic Oscillator 56.95 32.43

Price Performance

Historical Comparison
SYF
RPRX

About SYF Synchrony Financial

Synchrony Financial, originally a spinoff of GE Capital's retail financing business, is the largest provider of private-label credit cards in the United States by both outstanding receivables and purchasing volume. Synchrony partners with other firms to market its credit products in their physical stores as well as on their websites and mobile applications. Synchrony operates through three segments: retail card (private-label and co-branded general-purpose credit cards), payment solutions (promotional financing for large ticket purchases), and CareCredit (financing for elective healthcare procedures).

About RPRX Royalty Pharma plc

Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.

Share on Social Networks: